Inclusion criteria for this meta-analysis have to meet the following: (1) The subjects were diagnosed with lung cancer and received at least one PD-1/PD-L1 inhibitors; (2) Studies that reported the relationship between irAEs and curative effect in NSCLC; (3) Studies included hazard ratios (HRs) of OS and PFS, as well as available survival data of HRs and 95% confidence intervals (CIs) or p values; (4) Prospective or retrospective cohort studies. This evidence concerns the gene PDCD1 and lung cancer.